PCMA Statement on Prescription Drug Price Transparency Legislation

(Washington, D.C.) — Pharmaceutical Care Management Association (PCMA) President and CEO JC Scott issued the following statement on the U.S. House of Representatives’ vote on prescription drug price transparency legislation:

“PBMs support increasing transparency across the entire prescription drug supply chain. We will continue to review the legislation, and we look forward to working with Congress to reduce prescription drug costs for consumers.”

PBMs practice and support transparency for consumers, physicians, clients, and policymakers. PCMA’s principles on transparency include:

  • Providing real-time benefit tools, so physicians and patients know at the point of prescribing what drugs are on formulary and patients’ cost-sharing.
  • Providing information to clients on all contract terms, including how PBMs are paid for their services and negotiated rebates.
  • Providing government regulators, such as CMS for Medicare Part D, information on price concessions, costs, and service fees.